June 2023
Volume 64, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2023
Targeting protein kinase G for the treatment of degenerative diseases of the retina
Author Affiliations & Notes
  • Francois Paquet-Durand
    Institute for Ophthalmic Research, Universitatsklinikum Tubingen, Tubingen, Baden-Württemberg, Germany
    Mireca Medicines GmbH, Tübingen, Baden-Württemberg, Germany
  • Footnotes
    Commercial Relationships   Francois Paquet-Durand Graybug Vision, Inc., Code C (Consultant/Contractor), Mireca Medicines GmbH, Tübingen, Germany, Code O (Owner), Mireca Medicines GmbH, Tübingen, Germany, Code P (Patent)
  • Footnotes
    Support  European Union (transMed; H2020-MSCA-765441), Baden-Württemberg Foundation (BWST-WSF_006), the Charlotte and the Tistou Kerstan Foundation, the Hector Fellow Academy, the Deutsche Forschungsgemeinschaft (Project-Number 437036164 to V.N.), and the German Ministry for Education and Research (BMBF; TargetRD, 16GW0267K, 16GW0269, 16GW0270).
Investigative Ophthalmology & Visual Science June 2023, Vol.64, 2. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Francois Paquet-Durand; Targeting protein kinase G for the treatment of degenerative diseases of the retina. Invest. Ophthalmol. Vis. Sci. 2023;64(8):2.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Presentation Description : Excessively high levels of the second messenger molecule cyclic guanosine monophosphate (cGMP) can cause photoreceptor degeneration. In photoreceptors, cGMP acts on two prototypic targets: 1) the cyclic nucleotide gated (CNG) -channel, and 2) protein kinase G (PKG). The presentation will introduce the cyclic nucleotide CN238 as a new compound that interferes with cGMP-signalling in photoreceptor cells, specifically by inhibiting PKG. This compound was identified in a screen of cGMP-analogs and was shown to prevent photoreceptor loss in several different models for inherited retinal degeneration. Notably, treatment with CN238 preserved photoreceptor viability and function in the rd10 mouse model for retinal degeneration. Unexpectedly, CN238 also bestowed signficant functional protection of retinal ganglion cells in explanted and axotomized retinal cultures in vitro. Overall, the data shown highlights CN238 as a new and highly efficient drug for future treatments of retinal diseases. This includes inherited retinal degeneration affecting photoreceptors and diseases such as retinitis pigmentosa or Leber's congenital amaurosis, as well as common retinal diseases characterized by ganglion cell loss, such as in glaucoma.

This abstract was presented at the 2023 ARVO Annual Meeting, held in New Orleans, LA, April 23-27, 2023.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×